Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 595
interventional 490
Observational 93
Registry 12

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 230
Biological 58
Procedure 23
Drug|Procedure 22
Other 21
Device 18
Behavioral 14
Drug|Procedure|Radiation 14
Biological|Drug 10
Drug|Other 8
Drug|placebo 7
Biological|Drug|Procedure 6
Biological|Drug|Other|Procedure|Radiation 5
Biological|Drug|Procedure|Radiation 5
Device|Drug|Procedure 5
Biological|Other 3
Biological|Procedure 3
Drug|Other|Procedure 3
Drug|Other|Procedure|Radiation 3
Drug|Radiation 3
Biological|Device|Drug 2
Biological|Drug|Radiation 2
Dietary Supplement 2
Drug|Other|Radiation 2
Other|Procedure 2
Behavioral|Other|Procedure 1
Biological|Device 1
Biological|Device|Drug|Other 1
Biological|Device|Drug|Radiation 1
Biological|Drug|Other|Procedure 1
Biological|placebo 1
Device|Drug 1
Device|Drug|Radiation 1
Device|placebo 1
Device|Procedure 1
Diagnostic Test 1
Dietary Supplement|Other 1
Drug|Genetic 1
Drug|Genetic|Other 1
Drug|Genetic|Radiation 1
Drug|Other|placebo|Procedure 1
Genetic 1
Procedure|Radiation 1
Radiation 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 272
France 28
China 23
Canada 17
Italy 15
NA 9
United Kingdom 7
United States|Canada 7
Belgium 5
Japan 5
Netherlands 5
United States|France 4
United States|United Kingdom 4
Australia 3
Germany 3
Austria 2
Denmark 2
Israel 2
Korea, Republic of 2
Sweden 2
Switzerland 2
Turkey 2
United States|Australia 2
United States|Germany|Italy 2
United States|Italy 2
Australia|Canada|Korea, Republic of 1
Australia|New Zealand 1
Australia|United Kingdom 1
Austria|Czechia|Germany|Italy|Poland|United Kingdom 1
Belarus 1
Belgium|Canada|Croatia|Germany|Portugal|United Kingdom 1
Belgium|Canada|Germany|United Kingdom 1
Belgium|Netherlands 1
Belgium|Romania 1
Brazil 1
Egypt 1
Finland|Germany|Poland|Sweden 1
France|Germany|Switzerland 1
Germany|Greece|Israel|Italy|United Kingdom 1
Germany|Italy|Spain|Sweden 1
Germany|Netherlands|United Kingdom 1
India 1
Ireland 1
Netherlands|Spain|Switzerland 1
Russian Federation 1
Saudi Arabia 1
Singapore 1
Spain 1
United States|Argentina|Belgium|Brazil|Chile|Finland|France|Greece|Israel|Italy|Mexico|Peru|Russian Federation|Spain|Turkey|Ukraine|United Kingdom 1
United States|Australia|Austria|Belgium|Brazil|Canada|France|Germany|Hungary|Ireland|Israel|Italy|Korea, Republic of|Lithuania|Mexico|Poland|Portugal|Romania|Russian Federation|Singapore|South Africa|Spain|Sweden|Taiwan|United Kingdom 1
United States|Australia|Austria|Bulgaria|Canada|Czechia|France|Germany|Greece|Hong Kong|Hungary|Ireland|Italy|Japan|Korea, Republic of|Lithuania|Malaysia|New Zealand|Poland|Portugal|Russian Federation|Singapore|Slovakia|Spain|Switzerland|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Australia|Austria|Canada|France|Germany|Italy|Spain|Sweden 1
United States|Australia|Bulgaria|Poland|Spain|Thailand|Ukraine 1
United States|Australia|Canada 1
United States|Australia|Canada|France|Germany|Italy|Korea, Republic of|Spain|United Kingdom 1
United States|Australia|Canada|Germany|Israel|Italy 1
United States|Australia|Canada|Ireland|Korea, Republic of 1
United States|Australia|Germany 1
United States|Australia|Israel|Poland|Spain|Turkey 1
United States|Australia|Korea, Republic of|Spain|United Kingdom 1
United States|Austria|Belgium|Canada|France|Germany|Italy|Netherlands|Spain|United Kingdom 1
United States|Belgium 1
United States|Belgium|France|Netherlands|Spain|Sweden 1
United States|Belgium|Netherlands 1
United States|Brazil|France|Israel|Italy|Netherlands|Portugal|Singapore|Spain|United Kingdom 1
United States|Canada|Denmark 1
United States|Canada|Denmark|France|Germany|Italy|Netherlands|Norway|Poland|Spain|United Kingdom 1
United States|Canada|Georgia|Moldova, Republic of|Poland|Spain|Ukraine 1
United States|Canada|Italy|United Kingdom 1
United States|Denmark|Germany 1
United States|France|Germany|Italy|Netherlands|United Kingdom 1
United States|France|Germany|Italy|Norway|United Kingdom 1
United States|France|Germany|Italy|Spain 1
United States|France|Germany|Spain 1
United States|France|Italy|Netherlands|Spain|Switzerland 1
United States|France|Korea, Republic of 1
United States|France|Netherlands|United Kingdom 1
United States|France|Spain|United Kingdom 1
United States|Germany 1
United States|Germany|Italy|Spain 1
United States|Germany|Spain|United Kingdom 1
United States|Hungary|Israel|Italy|Spain 1
United States|Israel|Netherlands|Spain 1
United States|Italy|Netherlands|Singapore|Spain 1
United States|Japan|Netherlands|Spain 1
United States|Netherlands|Spain 1
United States|Netherlands|Switzerland|United Kingdom 1
United States|Singapore 1

Sites per Study

Site_count Study_Count
1 278
2 35
3 31
4 15
5 21
6 8
7 9
8 14
9 7
10 12
11 7
12 5
13 3
14 3
15 6
16 3
17 2
18 2
19 2
20 3
21 1
22 1
23 1
24 3
25 2
27 1
28 2
29 1
30 1
35 1
36 1
39 2
42 1
48 1
52 1
59 1
68 1
101 1
309 1

Phase

Phase Study_Count
Phase 1 164
Phase 2 127
N/A 71
Phase 1/Phase 2 70
Phase 3 28
Early Phase 1 12
Phase 2/Phase 3 9
Phase 4 9

Number of Arms

Number_of_Arms Count_of_Studies
1 268
2 112
3 30
4 20
5 3
6 4
7 2
8 3
9 2
10 2
11 1
14 1
17 1
NA 41

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 9.00 7.0000 4.00000 3.00000 2.0000 50 6.0000 7.0000
1st Qu. 16.00 28.0000 20.00000 27.00000 20.5000 50 62.2500 32.0000
Median 20.00 50.0000 36.00000 54.50000 47.0000 101 150.0000 51.0000
Mean 39.25 126.3239 60.62963 86.77143 67.3622 117 424.7692 234.4444
3rd Qu. 72.00 100.0000 74.25000 108.25000 81.5000 126 281.7500 120.0000
Max. 100.00 2000.0000 661.00000 500.00000 500.0000 250 5305.0000 1500.0000

Trial Group Type

group_type Group_Count
Experimental 682
Active Comparator 63
NA 41
Other 39
No Intervention 25
Placebo Comparator 10

Intervention Model

intervention_model Study_Count
Single Group Assignment 331
Parallel Assignment 134
NA 9
Sequential Assignment 8
Crossover Assignment 6
Factorial Assignment 2

Primary Purpose

primary_purpose Study_Count
Treatment 395
Prevention 35
Supportive Care 33
Other 12
Diagnostic 5
NA 4
Basic Science 3
Health Services Research 2
Device Feasibility 1

Observational Studies

Studies by Country

Country Study_Count
United States 39
France 17
Italy 7
NA 5
Korea, Republic of 3
Netherlands 3
Spain 3
China 2
Egypt 2
Austria|Germany 1
Canada 1
Finland 1
Germany 1
Israel 1
Switzerland 1
Turkey 1
United Kingdom 1
United States|Canada 1
United States|Canada|Spain|United Kingdom 1
United States|Israel 1
United States|Puerto Rico 1

Sites per Study

Site_count Study_Count
1 68
2 4
3 3
6 1
9 2
12 1
13 1
15 2
16 1
22 1
23 1
26 2
29 1
32 1
33 1
44 1
81 1
144 1

Enrollment Metrics

Measure Observational
Min 10
1st Qu 60
Median 160
Mean 1091049
3rd Qu 454
Max 99999999

Observation Model

observational_model Study_Count
Cohort 51
Case-Only 22
Other 9
Case-Control 6
NA 4
Case Control 1

Time Perspective

time_perspective Study_Count
Prospective 71
Retrospective 13
NA 4
Cross-Sectional 3
Other 2

Registries

Studies by Country

Country Study_Count
United States 3
Germany 2
Austria 1
China 1
Germany|Netherlands 1
Italy 1
Malawi 1
Malaysia 1
United States|Israel|Italy|Netherlands 1

Sites per Study

Site_count Study_Count
1 8
2 1
6 1
14 1
18 1

Enrollment Metrics

Measure Registries
Min 30.000
1st Qu 280.000
Median 650.000
Mean 2070.833
3rd Qu 2375.000
Max 10000.000

Registry Model

observational_model Study_Count
Cohort 5
Other 4
Case-Only 3

Time Perspective

time_perspective Study_Count
Prospective 8
Other 3
Cross-Sectional 1

Follow-up

target_duration Study_Count
5 Years 3
1 Year 2
1 Day 1
10 Years 1
100 Years 1
20 Years 1
30 Days 1
4 Years 1
6 Months 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT02791737 Exercise Prehab in Older Adults With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02791737 Active, not recruiting Ohio State University Comprehensive Cancer Center 2020-12-31
NCT03365791 PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03365791 Active, not recruiting Novartis 2019-02-21
NCT04214093 A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors https://ClinicalTrials.gov/show/NCT04214093 Recruiting AstraZeneca 2022-04-29
NCT04035447 Symptom Management for YA Cancer Survivors https://ClinicalTrials.gov/show/NCT04035447 Recruiting Duke University 2025-10-01
NCT03955783 Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03955783 Recruiting Vanderbilt-Ingram Cancer Center 2021-01-31
NCT03373656 Vaccination for Children of H&O and Their Parents https://ClinicalTrials.gov/show/NCT03373656 Recruiting Children’s Cancer Group, China 2019-09-30
NCT03823651 A Research Program Targeting Pre- and Peri-transplant Optimization Program (R-PPOP) https://ClinicalTrials.gov/show/NCT03823651 Recruiting Duke University 2021-01-31
NCT03821519 Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant https://ClinicalTrials.gov/show/NCT03821519 Recruiting A.O. Ospedale Papa Giovanni XXIII 2022-05-31
NCT03344705 Safety and Efficacy Evaluation of IM19 Cells https://ClinicalTrials.gov/show/NCT03344705 Recruiting Beijing Immunochina Medical Science & Technology Co., Ltd. 2020-10-01
NCT03328078 A Study of CA-4948 in Patients With Relapsed or Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03328078 Recruiting Curis, Inc. 2020-12-31
NCT03320642 GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease https://ClinicalTrials.gov/show/NCT03320642 Recruiting Incyte Corporation 2020-07-31
NCT03263637 Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies https://ClinicalTrials.gov/show/NCT03263637 Active, not recruiting AstraZeneca 2021-12-31
NCT03248479 Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT03248479 Recruiting Forty Seven, Inc. 2020-09-30
NCT03219268 A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms https://ClinicalTrials.gov/show/NCT03219268 Recruiting MacroGenics 2020-06-30
NCT03218683 Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. https://ClinicalTrials.gov/show/NCT03218683 Active, not recruiting AstraZeneca 2022-01-11
NCT03168815 Low-Flow vs. High-Flow Nasal Cannula for Hypoxemic Immunocompromised Patients During Diagnostic Bronchoscopy https://ClinicalTrials.gov/show/NCT03168815 Recruiting Mount Sinai Hospital, Canada 2020-12-31
NCT03162536 A Study of ARQ 531 in Patients With Selected Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03162536 Recruiting ArQule 2021-12-31
NCT03159702 Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation https://ClinicalTrials.gov/show/NCT03159702 Recruiting Medical College of Wisconsin 2021-07-01
NCT03149055 Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT) https://ClinicalTrials.gov/show/NCT03149055 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-05-31
NCT03145181 Dose Escalation Study of JNJ-64007957, a Humanized BCMA CD3 DuoBody® Antibody, in Participants With Relapsed or Refractory Multiple Myeloma https://ClinicalTrials.gov/show/NCT03145181 Recruiting Janssen Research & Development, LLC 2021-03-29
NCT03136445 TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia https://ClinicalTrials.gov/show/NCT03136445 Recruiting NHS Blood and Transplant 2020-12-30
NCT03133520 Effectiveness of High Flow Oxygen Therapy in Patients With Hematologic Malignancy Acute Hypoxemic Respiratory Failure https://ClinicalTrials.gov/show/NCT03133520 Completed TC Erciyes University 2018-09-14
NCT03131934 Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant https://ClinicalTrials.gov/show/NCT03131934 Recruiting University College, London 2020-06-30
NCT03128359 High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT03128359 Recruiting City of Hope Medical Center 2021-01-31
NCT03125577 Combination CAR-T Cell Therapy Targeting Hematological Malignancies https://ClinicalTrials.gov/show/NCT03125577 Recruiting Shenzhen Geno-Immune Medical Institute 2019-07-31
NCT03106662 Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT03106662 Completed Ankara University 2017-07-31
NCT03106428 A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies https://ClinicalTrials.gov/show/NCT03106428 Completed MedImmune LLC 2020-01-03
NCT03096821 Extended Analysis for Leukemia/Lymphoma Treatment https://ClinicalTrials.gov/show/NCT03096821 Recruiting Medical University of Vienna 2019-09-30
NCT03094026 Cognitive Training Intervention and Attitudes Towards Genetics https://ClinicalTrials.gov/show/NCT03094026 Recruiting University of Alabama at Birmingham 2024-07-31
NCT03087227 Shared Health Information System for Febrile Neutropenia https://ClinicalTrials.gov/show/NCT03087227 Recruiting University of Paris 13 2019-11-30
NCT03085173 A Trial of “Armored” CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03085173 Recruiting Memorial Sloan Kettering Cancer Center 2021-03-31
NCT03083327 Prophylactic Early PN in HPT/BMT https://ClinicalTrials.gov/show/NCT03083327 Recruiting University of Sydney 2021-05-01
NCT03082209 A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03082209 Recruiting AbbVie 2022-08-01
NCT03067155 CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation. https://ClinicalTrials.gov/show/NCT03067155 Recruiting University Hospital, Ghent 2022-12-31
NCT03052777 Using Telephone Counselling to Improve Exercise Participation in Hematologic Cancer Survivors https://ClinicalTrials.gov/show/NCT03052777 Completed University of Alberta 2017-08-01
NCT03032783 A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity https://ClinicalTrials.gov/show/NCT03032783 Recruiting Thomas Jefferson University 2020-07-24
NCT03023631 Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT03023631 Recruiting M.D. Anderson Cancer Center 2020-04-30
NCT02988466 Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haploidentical Related Hematopoietic https://ClinicalTrials.gov/show/NCT02988466 Recruiting Masonic Cancer Center, University of Minnesota 2021-01-31
NCT02966457 A Study of DEcolonization in Patients With HAematological Malignancies (DEHAM) https://ClinicalTrials.gov/show/NCT02966457 Completed Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology 2017-12-31
NCT02964325 Efficacy of Mirasol-treated Apheresis Platelets in Patients With Hypoproliferative Thrombocytopenia https://ClinicalTrials.gov/show/NCT02964325 Recruiting Terumo BCTbio 2021-11-30
NCT02955966 PET/CT Guided Antifungal Stewardship in Invasive Pulmonary Aspergillosis https://ClinicalTrials.gov/show/NCT02955966 Recruiting Assistance Publique - Hôpitaux de Paris 2020-08-31
NCT02944045 Effect of Steroids During Pneumocystis Infection Among Non HIV Immunocompromised Patients https://ClinicalTrials.gov/show/NCT02944045 Recruiting Assistance Publique - Hôpitaux de Paris 2019-10-31
NCT02924402 Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02924402 Recruiting Xencor, Inc. 2020-08-31
NCT02880709 The Effect of Special Diets in Hematological Cancer Patients https://ClinicalTrials.gov/show/NCT02880709 Completed University of Copenhagen 2014-05-31
NCT02880293 Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor https://ClinicalTrials.gov/show/NCT02880293 Recruiting Memorial Sloan Kettering Cancer Center 2021-08-31
NCT02849886 T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation. https://ClinicalTrials.gov/show/NCT02849886 Recruiting Centre Hospitalier Universitaire de Besancon 2020-12-31
NCT02841124 Decision to Limit or Withdraw Specific Therapies for Advanced Cancer and Hematological Malignancies. https://ClinicalTrials.gov/show/NCT02841124 Completed Centre Hospitalier Universitaire de Besancon 2011-08-31
NCT02834156 Impact of Child Positioning on Pain During a Lumbar Puncture https://ClinicalTrials.gov/show/NCT02834156 Completed Centre Hospitalier Universitaire de Nice 2017-08-23
NCT02828878 Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT02828878 Recruiting Cellect Biotechnology 2020-07-31
NCT02813837 Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02813837 Recruiting Innovative Cellular Therapeutics Co., Ltd. 2021-01-31
NCT02805075 Fructooligosaccharides in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT02805075 Completed Stanford University 2017-11-17
NCT02745743 Phase I Trial of BAY1251152 for Advanced Blood Cancers https://ClinicalTrials.gov/show/NCT02745743 Completed Bayer 2018-08-03
NCT02743351 Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02743351 Recruiting Fate Therapeutics 2020-04-30
NCT02730312 PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02730312 Recruiting Xencor, Inc. 2020-08-31
NCT02712905 An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies https://ClinicalTrials.gov/show/NCT02712905 Recruiting Incyte Corporation 2021-06-17
NCT02711852 A Long-term, Continued Treatment and Follow-up Study in Subjects With Hematologic Malignancies Treated With Duvelisib (IPI-145) https://ClinicalTrials.gov/show/NCT02711852 Active, not recruiting Verastem, Inc. 2020-06-30
NCT02698189 A Dose Exploration Study With MK-8628 in Participants With Selected Hematologic Malignancies (MK-8628-005) https://ClinicalTrials.gov/show/NCT02698189 Active, not recruiting Merck Sharp & Dohme Corp. 2018-01-18
NCT02696408 Efficacy of Prophylactic Low Level Laser Therapy (LLLT) Performed by Nurses for Decreasing Severity of Oral Mucositis During Hematopoietic Stem Cell (HSC) Transplantation https://ClinicalTrials.gov/show/NCT02696408 Completed Institut de Cancérologie de la Loire 2019-11-07
NCT02684617 Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155) https://ClinicalTrials.gov/show/NCT02684617 Completed Merck Sharp & Dohme Corp. 2020-02-06
NCT02680795 Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes https://ClinicalTrials.gov/show/NCT02680795 Recruiting Acrotech Biopharma LLC 2021-03-31
NCT02678338 CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies https://ClinicalTrials.gov/show/NCT02678338 Completed Forty Seven, Inc. 2018-11-30
NCT02668315 Expanded Cord Blood in Patients in Need of an Allogeneic Stem Cell Transplant https://ClinicalTrials.gov/show/NCT02668315 Completed Maisonneuve-Rosemont Hospital 2018-08-31
NCT02663518 A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors https://ClinicalTrials.gov/show/NCT02663518 Recruiting Trillium Therapeutics Inc. 2021-06-30
NCT02650791 Platelet Transfusion Requirements in Hematopoietic Transplantation Pilot Study https://ClinicalTrials.gov/show/NCT02650791 Completed Ottawa Hospital Research Institute 2019-06-30
NCT02639559 Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies https://ClinicalTrials.gov/show/NCT02639559 Active, not recruiting Washington University School of Medicine 2018-04-12
NCT02635984 Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens https://ClinicalTrials.gov/show/NCT02635984 Completed Augusta University 2017-12-31
NCT02634294 Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT https://ClinicalTrials.gov/show/NCT02634294 Recruiting Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 2020-12-31
NCT02623309 Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients https://ClinicalTrials.gov/show/NCT02623309 Recruiting Institut Paoli-Calmettes 2019-02-28
NCT02611063 Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant https://ClinicalTrials.gov/show/NCT02611063 Recruiting Duke University 2020-01-31
NCT02600208 Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device https://ClinicalTrials.gov/show/NCT02600208 Recruiting Medical College of Wisconsin 2020-12-31
NCT02593123 Allogeneic Stem Cell Transplantationin Relapsed Hematological Malignancy: Early GVHD Prophylaxis https://ClinicalTrials.gov/show/NCT02593123 Active, not recruiting Virginia Commonwealth University 2025-12-31
NCT02583035 Telephone OncoGériatric Followed in the Management of Elderly Patients Treated for Cancer or Haematological Malignancy https://ClinicalTrials.gov/show/NCT02583035 Completed Centre Francois Baclesse 2018-02-16
NCT01028716 Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01028716 Recruiting Fred Hutchinson Cancer Research Center 2024-01-04
NCT02576496 Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02576496 Recruiting Mundipharma-EDO GmbH 2021-03-31
NCT02790515 Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation https://ClinicalTrials.gov/show/NCT02790515 Recruiting St. Jude Children’s Research Hospital 2020-08-31
NCT02376699 Safety Study of SEA-CD40 in Cancer Patients https://ClinicalTrials.gov/show/NCT02376699 Recruiting Seattle Genetics, Inc. 2021-10-31
NCT03403075 Therapeutic Education in Physical Activity (ETAF) https://ClinicalTrials.gov/show/NCT03403075 Completed Arcispedale Santa Maria Nuova-IRCCS 2019-08-31
NCT03399799 Dose Escalation Study of JNJ-64407564 in Participants With Relapsed or Refractory Multiple Myeloma https://ClinicalTrials.gov/show/NCT03399799 Recruiting Janssen Research & Development, LLC 2021-01-21
NCT02566304 Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02566304 Recruiting Thomas Jefferson University 2020-07-23
NCT02543879 Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02543879 Completed Forma Therapeutics, Inc. 2019-03-31
NCT02534649 Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials https://ClinicalTrials.gov/show/NCT02534649 Recruiting Institut Bergonié 2020-03-31
NCT02530034 Hu8F4 in Treating Patients With Advanced Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02530034 Recruiting M.D. Anderson Cancer Center 2022-01-31
NCT02514083 A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) https://ClinicalTrials.gov/show/NCT02514083 Active, not recruiting National Institutes of Health Clinical Center (CC) 2019-10-02
NCT02512666 Non Invasive Optical Imaging of WBC Count https://ClinicalTrials.gov/show/NCT02512666 Completed Massachusetts General Hospital 2017-09-30
NCT02508038 Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors https://ClinicalTrials.gov/show/NCT02508038 Recruiting University of Wisconsin, Madison 2021-05-31
NCT02504047 Use of Haploidentical Related Donors for Patients Without Matched Sibling, Unrelated Donor or Cord Blood Units https://ClinicalTrials.gov/show/NCT02504047 Completed University of Calgary 2019-02-01
NCT02503033 A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02503033 Recruiting Hutchison Medipharma Limited 2020-12-31
NCT02500550 Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor https://ClinicalTrials.gov/show/NCT02500550 Completed Kiadis Pharma 2018-07-31
NCT02494258 A Study to Evaluate Long-term Safety in Subjects With Solid Tumors and Hematological Disorders. https://ClinicalTrials.gov/show/NCT02494258 Active, not recruiting Celgene 2021-02-28
NCT02492789 A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients https://ClinicalTrials.gov/show/NCT02492789 Completed Atridia Pty Ltd. 2019-03-01
NCT02492737 Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation https://ClinicalTrials.gov/show/NCT02492737 Completed Agios Pharmaceuticals, Inc. 2018-03-21
NCT02487069 Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy https://ClinicalTrials.gov/show/NCT02487069 Completed Nanfang Hospital of Southern Medical University 2020-01-31
NCT02477878 Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant https://ClinicalTrials.gov/show/NCT02477878 Active, not recruiting Bellicum Pharmaceuticals 2018-03-26
NCT02464696 Early Non Invasive Ventilation and Hematological Malignancies https://ClinicalTrials.gov/show/NCT02464696 Recruiting M.D. Anderson Cancer Center 2020-10-01
NCT02443831 CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies https://ClinicalTrials.gov/show/NCT02443831 Active, not recruiting University College, London 2020-10-31
NCT02420873 An Open-label Phase II Study of Lorvotuzumab Mertansine https://ClinicalTrials.gov/show/NCT02420873 Completed M.D. Anderson Cancer Center 2017-06-06
NCT03386526 APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03386526 Recruiting Ascentage Pharma Group Inc. 2020-09-11
NCT02372357 A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area https://ClinicalTrials.gov/show/NCT02372357 Completed Universitaire Ziekenhuizen Leuven 2014-08-31
NCT02367196 A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers https://ClinicalTrials.gov/show/NCT02367196 Active, not recruiting Celgene 2021-02-22
NCT02362035 ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02362035 Active, not recruiting Acerta Pharma BV 2021-05-31
NCT02361346 Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL https://ClinicalTrials.gov/show/NCT02361346 Recruiting Molecular Templates, Inc. 2021-05-31
NCT02359838 Patient-Centered Care for the Older Adult With Hematologic Malignancy https://ClinicalTrials.gov/show/NCT02359838 Active, not recruiting Dana-Farber Cancer Institute 2025-01-31
NCT02352558 A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02352558 Completed Boston Biomedical, Inc 2018-12-14
NCT02342613 Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation https://ClinicalTrials.gov/show/NCT02342613 Recruiting Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2023-01-31
NCT02333162 Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT02333162 Recruiting University of Chicago 2020-12-01
NCT02333058 Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies https://ClinicalTrials.gov/show/NCT02333058 Completed medac GmbH 2016-12-24
NCT02329847 A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02329847 Active, not recruiting Janssen Research & Development, LLC 2020-07-31
NCT02323867 Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02323867 Recruiting Children’s Hospital of Philadelphia 2024-10-31
NCT02321345 Pretransplant Evaluation by Supportive Care Team for Patients Undergoing HCT for Hematological Malignancies https://ClinicalTrials.gov/show/NCT02321345 Completed Medical College of Wisconsin 2017-10-31
NCT02304809 Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations https://ClinicalTrials.gov/show/NCT02304809 Active, not recruiting UNICANCER 2019-05-07
NCT02270788 Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02270788 Completed St. Jude Children’s Research Hospital 2016-10-17
NCT02265731 Study Evaluating Venetoclax in Subjects With Hematological Malignancies https://ClinicalTrials.gov/show/NCT02265731 Active, not recruiting AbbVie 2021-01-24
NCT02223052 Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02223052 Completed Celgene 2018-06-11
NCT02215070 Pasireotide in Prevention of GI Toxicity https://ClinicalTrials.gov/show/NCT02215070 Completed Duke University 2019-02-28
NCT02203903 Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies https://ClinicalTrials.gov/show/NCT02203903 Recruiting Children’s National Research Institute 2024-11-30
NCT02193880 Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT) https://ClinicalTrials.gov/show/NCT02193880 Completed University of Alabama at Birmingham 2018-03-13
NCT02167958 Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source https://ClinicalTrials.gov/show/NCT02167958 Completed University of Pittsburgh 2019-09-21
NCT02160951 Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02160951 Completed Novartis 2016-05-31
NCT02149329 Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO https://ClinicalTrials.gov/show/NCT02149329 Completed VU University Medical Center 2019-08-05
NCT02145403 Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02145403 Active, not recruiting University of Michigan Rogel Cancer Center 2018-11-26
NCT02139280 Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy https://ClinicalTrials.gov/show/NCT02139280 Active, not recruiting Dartmouth-Hitchcock Medical Center 2019-07-31
NCT02129582 Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02129582 Active, not recruiting Case Comprehensive Cancer Center 2019-03-15
NCT02122081 Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02122081 Recruiting Ohio State University Comprehensive Cancer Center 2019-12-31
NCT02120157 Trial of Myeloablative Conditioning & Transplantation of Partially Human Leukocyte Antigen (HLA)-Mismatched Marrow With Post-transplant Cyclophosphamide for Peds Pts w/ Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02120157 Active, not recruiting Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2018-06-15
NCT02106650 Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT02106650 Completed Acrotech Biopharma LLC 2018-10-31
NCT01351350 Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies https://ClinicalTrials.gov/show/NCT01351350 Completed Takeda 2017-09-15
NCT02074839 Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation https://ClinicalTrials.gov/show/NCT02074839 Recruiting Agios Pharmaceuticals, Inc. 2020-12-31
NCT02074436 PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid) https://ClinicalTrials.gov/show/NCT02074436 Recruiting Emory University 2021-05-31
NCT02061761 Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02061761 Active, not recruiting Bristol-Myers Squibb 2020-05-15
NCT01317927 A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies https://ClinicalTrials.gov/show/NCT01317927 Completed Spectrum Pharmaceuticals, Inc 2015-06-30
NCT01315132 A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01315132 Completed Thomas Jefferson University 2018-09-19
NCT02046291 Safety of Romiplostim (Nplate®) Following UCBT https://ClinicalTrials.gov/show/NCT02046291 Active, not recruiting Masonic Cancer Center, University of Minnesota 2020-12-31
NCT02038777 A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02038777 Active, not recruiting Pfizer 2020-11-03
NCT02034981 Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1 https://ClinicalTrials.gov/show/NCT02034981 Active, not recruiting UNICANCER 2019-06-30
NCT02032446 Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT02032446 Recruiting A.O. Ospedale Papa Giovanni XXIII 2016-09-30
NCT04018248 BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I) https://ClinicalTrials.gov/show/NCT04018248 Recruiting Boryung Pharmaceutical Co., Ltd 2023-12-31
NCT01982682 Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor https://ClinicalTrials.gov/show/NCT01982682 Completed Thomas Jefferson University 2017-03-27
NCT01981187 LGX818 for Patients With BRAFV600 Mutated Tumors https://ClinicalTrials.gov/show/NCT01981187 Completed Array BioPharma 2015-09-30
NCT01943851 A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01943851 Completed GlaxoSmithKline 2020-04-28
NCT01930162 Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant https://ClinicalTrials.gov/show/NCT01930162 Completed Novartis 2016-08-29
NCT01916057 Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis https://ClinicalTrials.gov/show/NCT01916057 Completed Assistance Publique - Hôpitaux de Paris 2017-06-01
NCT01915498 Phase 1/2 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation https://ClinicalTrials.gov/show/NCT01915498 Active, not recruiting Celgene 2019-07-25
NCT01912222 Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction https://ClinicalTrials.gov/show/NCT01912222 Completed Millennium Pharmaceuticals, Inc. 2015-03-31
NCT01900509 Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01900509 Completed St. Jude Children’s Research Hospital 2016-05-31
NCT01888952 Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013) https://ClinicalTrials.gov/show/NCT01888952 Completed The University of Texas Health Science Center at San Antonio 2015-01-31
NCT01885897 IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT https://ClinicalTrials.gov/show/NCT01885897 Active, not recruiting Masonic Cancer Center, University of Minnesota 2019-07-31
NCT01885195 MEK162 for Patients With RAS/RAF/MEK Activated Tumors https://ClinicalTrials.gov/show/NCT01885195 Completed Array BioPharma 2015-10-31
NCT01854567 P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01854567 Completed Mesoblast, Ltd. 2016-09-23
NCT01853358 Phase I of Infusion of Selected Donor NK Cells After Allogeneic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT01853358 Completed Institut Paoli-Calmettes 2018-03-15
NCT01844869 An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate https://ClinicalTrials.gov/show/NCT01844869 Completed Teva Pharmaceutical Industries 2014-12-31
NCT01839916 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01839916 Completed University of Chicago 2018-08-31
NCT01830010 A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies https://ClinicalTrials.gov/show/NCT01830010 Completed Novartis 2018-08-21
NCT01827579 Infusion of Depleted T Cells Following Unrelated Donor Stem Cell Transplant (ICAT) https://ClinicalTrials.gov/show/NCT01827579 Active, not recruiting University College, London 2020-07-31
NCT01810588 Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation https://ClinicalTrials.gov/show/NCT01810588 Recruiting Weill Medical College of Cornell University 2021-12-31
NCT01807611 Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy https://ClinicalTrials.gov/show/NCT01807611 Active, not recruiting St. Jude Children’s Research Hospital 2020-07-31
NCT01802879 Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator https://ClinicalTrials.gov/show/NCT01802879 Completed Novartis 2018-11-19
NCT01799889 Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01799889 Completed Gilead Sciences 2017-09-14
NCT01794299 Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor https://ClinicalTrials.gov/show/NCT01794299 Completed Kiadis Pharma 2016-06-30
NCT01790568 Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01790568 Completed University of Michigan Rogel Cancer Center 2017-01-01
NCT01785810 Phase II Maraviroc for GVHD Prevention https://ClinicalTrials.gov/show/NCT01785810 Completed Abramson Cancer Center of the University of Pennsylvania 2016-11-11
NCT01767766 Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01767766 Completed TG Therapeutics, Inc. 2018-02-28
NCT01760655 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01760655 Recruiting Thomas Jefferson University 2021-03-31
NCT01758484 Supportive Care for Patients With Hematological Malignancies Undergoing Hematopoietic Cell Transplant https://ClinicalTrials.gov/show/NCT01758484 Completed Fred Hutchinson Cancer Research Center 2014-11-30
NCT01755000 Study of Hypotensive Hematopoietic Malignancy Patients’ USCOM Readings https://ClinicalTrials.gov/show/NCT01755000 Completed Washington University School of Medicine 2013-04-30
NCT01725555 A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors https://ClinicalTrials.gov/show/NCT01725555 Completed Axelar AB 2013-12-31
NCT01725022 A Controlled Study of Stem Cell Transplantation Medical Home Care Compared to Standard Hospital Care https://ClinicalTrials.gov/show/NCT01725022 Completed Duke University 2017-09-30
NCT01724528 Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01724528 Completed Menarini Group 2013-10-31
NCT01687231 Infection Rates of Myeloablative Allo SCT Recipients Receiving Neutropenic Diets Versus Non-Neutropenic Diets https://ClinicalTrials.gov/show/NCT01687231 Completed Duke University 2011-12-31
NCT01682226 Myeloablative Unrelated Donor Cord Blood Transplantation With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cells for Patients With High Risk Hematological Malignancies https://ClinicalTrials.gov/show/NCT01682226 Active, not recruiting Memorial Sloan Kettering Cancer Center 2020-09-30
NCT01664910 CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT01664910 Active, not recruiting M.D. Anderson Cancer Center 2021-10-31
NCT01658319 Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01658319 Completed Case Comprehensive Cancer Center 2015-02-28
NCT01635712 Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies https://ClinicalTrials.gov/show/NCT01635712 Completed Esanex Inc. 2016-01-31
NCT01627275 Naive T-Cell Depleted DLI Following Allo Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01627275 Completed Duke University 2017-02-24
NCT01607892 Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer https://ClinicalTrials.gov/show/NCT01607892 Completed Karyopharm Therapeutics Inc 2016-06-30
NCT01606033 Study of Stress and Life Quality of Patients Participating in Clinical Trials Versus Patients Non Participating https://ClinicalTrials.gov/show/NCT01606033 Completed Centre Oscar Lambret 2014-01-31
NCT01597219 Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers https://ClinicalTrials.gov/show/NCT01597219 Active, not recruiting University College, London 2019-10-31
NCT01596257 Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT01596257 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-05-31
NCT01594723 A Study of LY2784544 in Participants With Myeloproliferative Neoplasms https://ClinicalTrials.gov/show/NCT01594723 Active, not recruiting Eli Lilly and Company 2015-03-20
NCT01576653 Prospective Clinical Evaluation of Beta-D-Glucan Assay in Blood and BAL https://ClinicalTrials.gov/show/NCT01576653 Recruiting Medical University of Graz 2019-06-30
NCT01572181 Study of a Reduced-toxicity Myeloablative Conditioning Regimen Using Fludarabine and Full Doses of Intravenous Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning Regimens https://ClinicalTrials.gov/show/NCT01572181 Completed Nantes University Hospital 2017-10-24
NCT01553461 Transplants With Unlicensed Preserved Cord Blood https://ClinicalTrials.gov/show/NCT01553461 Recruiting National Institutes of Health Clinical Center (CC) 2036-10-20
NCT01551524 Phase I Study of mPEG-R-Crisantaspase Given IV https://ClinicalTrials.gov/show/NCT01551524 Completed Jazz Pharmaceuticals 2015-02-28
NCT01531894 Continuation Study of the Oral AKT Inhibitor GSK2110183 https://ClinicalTrials.gov/show/NCT01531894 Completed Novartis 2018-06-20
NCT01530581 Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation https://ClinicalTrials.gov/show/NCT01530581 Completed King Faisal Specialist Hospital & Research Center 2012-06-30
NCT01523171 Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib https://ClinicalTrials.gov/show/NCT01523171 Completed Sanofi 2014-04-30
NCT01499147 Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01499147 Completed University of Illinois at Chicago 2013-05-31
NCT01491958 Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT01491958 Completed Ohio State University Comprehensive Cancer Center 2014-01-01
NCT01484470 Umbilical Cord Transplantation for the Elderly Population https://ClinicalTrials.gov/show/NCT01484470 Completed Loyola University 2018-11-21
NCT01474681 Safety and Tolerability of HSC835 in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01474681 Completed Novartis 2016-10-03
NCT01471067 Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01471067 Completed M.D. Anderson Cancer Center 2017-04-25
NCT01460719 A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults With Hematologic Malignancies (HM) Receiving Treatment With Anti-Cluster of Differentiation (CD) 20 Monoclonal Antibodies (V212-013) https://ClinicalTrials.gov/show/NCT01460719 Completed Merck Sharp & Dohme Corp. 2012-09-25
NCT01460420 Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation https://ClinicalTrials.gov/show/NCT01460420 Completed European Myeloma Network 2017-06-30
NCT01451502 Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units https://ClinicalTrials.gov/show/NCT01451502 Recruiting Masonic Cancer Center, University of Minnesota 2022-12-31
NCT01437787 Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT01437787 Completed Sanofi 2014-06-30
NCT01428973 Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens https://ClinicalTrials.gov/show/NCT01428973 Active, not recruiting University of Liege 2022-09-30
NCT01420783 Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia https://ClinicalTrials.gov/show/NCT01420783 Completed Sanofi 2012-11-30
NCT01420770 Phase 2 Study of SAR302503 in Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT01420770 Completed Sanofi 2014-04-30
NCT01416428 Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01416428 Completed Amgen 2019-08-12
NCT01380756 Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT01380756 Completed Amgen 2014-09-04
NCT01375842 A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors https://ClinicalTrials.gov/show/NCT01375842 Completed Genentech, Inc. 2018-09-30
NCT01374841 Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors https://ClinicalTrials.gov/show/NCT01374841 Recruiting European Institute of Oncology 2019-08-31
NCT01353625 Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. https://ClinicalTrials.gov/show/NCT01353625 Active, not recruiting Celgene 2020-12-28
NCT01349101 A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors https://ClinicalTrials.gov/show/NCT01349101 Recruiting Thomas Jefferson University 2020-12-31
NCT01345019 Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma https://ClinicalTrials.gov/show/NCT01345019 Completed Amgen 2016-07-19
NCT01344876 Phase I Study of OPB-51602 in Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01344876 Completed Otsuka Pharmaceutical Co., Ltd. 2014-04-30
NCT01344707 Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS) https://ClinicalTrials.gov/show/NCT01344707 Completed 4SC AG 2015-03-31
NCT01341301 Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01341301 Completed Thomas Jefferson University 2013-11-04
NCT01334060 WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation https://ClinicalTrials.gov/show/NCT01334060 Completed University Hospital Southampton NHS Foundation Trust 2013-02-28
NCT01332006 Intra-bone Cord Blood Transplantation https://ClinicalTrials.gov/show/NCT01332006 Recruiting Università degli Studi di Brescia 2019-12-31
NCT01328496 Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen https://ClinicalTrials.gov/show/NCT01328496 Completed St. Jude Children’s Research Hospital 2016-10-31
NCT01324323 Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer https://ClinicalTrials.gov/show/NCT01324323 Completed Celgene 2012-02-01
NCT01324310 Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer https://ClinicalTrials.gov/show/NCT01324310 Completed Celgene 2012-01-01
NCT01321346 A Study Of Panobinostat In Children With Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01321346 Completed Therapeutic Advances in Childhood Leukemia Consortium 2015-10-31
NCT04425642 Effects of Parenteral Nutrition in HSCT https://ClinicalTrials.gov/show/NCT04425642 Recruiting St. Petersburg State Pavlov Medical University 2020-11-01
NCT04347226 Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19 https://ClinicalTrials.gov/show/NCT04347226 Recruiting Columbia University 2021-09-30
NCT04331483 A Study to Assess a Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Allografts https://ClinicalTrials.gov/show/NCT04331483 Active, not recruiting Centre Leon Berard 2023-09-30
NCT04310592 Natural Killer Cell (CYNK-001) Infusions in Adults With AML https://ClinicalTrials.gov/show/NCT04310592 Recruiting Celularity Incorporated 2022-01-03
NCT04283097 Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects https://ClinicalTrials.gov/show/NCT04283097 Recruiting Kangpu Biopharmaceuticals, Ltd. 2021-12-30
NCT04283006 A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT04283006 Recruiting Zhejiang University 2023-05-23
NCT04280133 CAR T-CELL Therapy Educational Video Trial https://ClinicalTrials.gov/show/NCT04280133 Recruiting Massachusetts General Hospital 2021-12-31
NCT04227015 A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy https://ClinicalTrials.gov/show/NCT04227015 Recruiting Zhejiang University 2022-01-08
NCT04226989 A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy https://ClinicalTrials.gov/show/NCT04226989 Recruiting Zhejiang University 2022-02-05
NCT04205409 Nivolumab for Relapsed or Refractory Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT04205409 Recruiting University of Washington 2022-08-01
NCT04191941 Treatment of Hematological Malignancy With Novel CAR-T Cells. https://ClinicalTrials.gov/show/NCT04191941 Recruiting Timmune Biotech Inc. 2021-08-31
NCT04191187 Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT04191187 Recruiting H. Lee Moffitt Cancer Center and Research Institute 2022-12-31
NCT04184869 Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials https://ClinicalTrials.gov/show/NCT04184869 Recruiting Acrotech Biopharma LLC 2022-06-01
NCT04184414 The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies https://ClinicalTrials.gov/show/NCT04184414 Recruiting PersonGen BioTherapeutics (Suzhou) Co., Ltd. 2020-01-01
NCT04174053 Concordance Between 2 Means of Temperature Measure in Neutropenic Patients Hospitalized in Intensive Hematology Care Units https://ClinicalTrials.gov/show/NCT04174053 Recruiting Centre Henri Becquerel 2020-06-30
NCT04156256 CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies https://ClinicalTrials.gov/show/NCT04156256 Recruiting iCell Gene Therapeutics 2020-09-30
NCT04103879 US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia https://ClinicalTrials.gov/show/NCT04103879 Recruiting ExCellThera inc. 2021-12-31
NCT04098393 Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT04098393 Recruiting Memorial Sloan Kettering Cancer Center 2021-09-30
NCT04068597 Study to Evaluate CCS1477 in Haematological Malignancies https://ClinicalTrials.gov/show/NCT04068597 Recruiting CellCentric Ltd. 2020-12-31
NCT04057443 Nutritional and Physical Exercise Intervention in Older Patients With Malignant Hemopathies https://ClinicalTrials.gov/show/NCT04057443 Recruiting L’Hospitalet de Llobregat 2021-06-01
NCT04052126 An Individualized Physical Activity Program in Patients Over 65 Years With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT04052126 Recruiting Centre Leon Berard 2021-02-28
NCT04024618 Feasibility Study Comparing Enteral vs Parenteral Nutritional Outcomes in Autologous Stem Cell Transplant Patients https://ClinicalTrials.gov/show/NCT04024618 Recruiting Lawson Health Research Institute 2020-08-30
NCT04022239 Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant https://ClinicalTrials.gov/show/NCT04022239 Recruiting M.D. Anderson Cancer Center 2022-07-01
NCT04013685 A Study of Engineered Donor Grafts (TregGraft) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies https://ClinicalTrials.gov/show/NCT04013685 Recruiting Orca Biosystems, Inc. 2022-09-30
NCT04011293 A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies https://ClinicalTrials.gov/show/NCT04011293 Recruiting Shandong University 2020-07-31
NCT03983850 Optimizing PTCy Dose and Timing https://ClinicalTrials.gov/show/NCT03983850 Recruiting National Institutes of Health Clinical Center (CC) 2024-05-31
NCT03963024 Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT https://ClinicalTrials.gov/show/NCT03963024 Recruiting IRCCS San Raffaele 2019-12-31
NCT03961919 Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant https://ClinicalTrials.gov/show/NCT03961919 Active, not recruiting IRCCS San Raffaele 2019-12-31
NCT03960619 In Person and Mobile Health Coping Skills Training for Improving Symptom Management and Daily Steps in Hematopoietic Stem Cell Transplant Patients https://ClinicalTrials.gov/show/NCT03960619 Completed Duke University 2019-11-22
NCT03922035 CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant https://ClinicalTrials.gov/show/NCT03922035 Recruiting City of Hope Medical Center 2021-12-24
NCT03919214 Hypertension Management in Cancer Patients https://ClinicalTrials.gov/show/NCT03919214 Recruiting Duke University 2020-12-31
NCT03913949 A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03913949 Recruiting Ascentage Pharma Group Inc. 2021-03-31
NCT03913026 UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia https://ClinicalTrials.gov/show/NCT03913026 Recruiting Ciusss de L’Est de l’ÃŽle de Montréal 2023-12-31
NCT03908138 RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma https://ClinicalTrials.gov/show/NCT03908138 Recruiting Shandong Provincial Hospital 2021-12-31
NCT03903185 Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy https://ClinicalTrials.gov/show/NCT03903185 Recruiting Ain Shams University 2021-03-31
NCT03886831 A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03886831 Recruiting Prelude Therapeutics 2021-08-11
NCT03885947 VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT03885947 Recruiting Icahn School of Medicine at Mount Sinai 2021-01-17
NCT03882203 CLAME Sequential With Flu-Bu Conditioning for Refractory Acute Leukemia https://ClinicalTrials.gov/show/NCT03882203 Recruiting Shanghai Jiao Tong University School of Medicine 2021-08-30
NCT03850366 HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib https://ClinicalTrials.gov/show/NCT03850366 Recruiting Henry Ford Health System 2023-01-01
NCT03849651 TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03849651 Recruiting St. Jude Children’s Research Hospital 2024-07-01
NCT03844360 Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease https://ClinicalTrials.gov/show/NCT03844360 Recruiting Shandong University 2021-12-31
NCT03837899 Durvalumab and Tremelimumab for Pediatric Malignancies https://ClinicalTrials.gov/show/NCT03837899 Recruiting AstraZeneca 2021-10-18
NCT03837171 TRANSfusion in Patients With Onco-hematological Malignancies ResusciTated From Septic Shock https://ClinicalTrials.gov/show/NCT03837171 Recruiting Assistance Publique - Hôpitaux de Paris 2021-02-20
NCT03818334 Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies https://ClinicalTrials.gov/show/NCT03818334 Recruiting Hospital Israelita Albert Einstein 2021-11-01
NCT03812705 Fecal Microbiota Transplantation for Steroid Resistant/Dependent Acute GI GVHD https://ClinicalTrials.gov/show/NCT03812705 Recruiting Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 2022-12-31
NCT03806764 Cytomegalovirus (CMV) Reactivation in Allogeneic HSCT Recipient https://ClinicalTrials.gov/show/NCT03806764 Enrolling by invitation Melbourne Health 2020-03-31
NCT03804164 Psycho-Educational Cognition Intervention in Patients With Blood and Lymph Cancer https://ClinicalTrials.gov/show/NCT03804164 Recruiting City of Hope Medical Center 2020-06-24
NCT03802695 A Phase 1 Study of Engineered Donor Grafts (OrcaGraft) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03802695 Recruiting Orca Biosystems, Inc. 2022-07-01
NCT03801122 Evolution of Thromboelastography During Tranexamic Acid Treatment https://ClinicalTrials.gov/show/NCT03801122 Recruiting Institut de Cancérologie de la Loire 2021-01-01
NCT03800758 Expressive Helping for Stem Cell Transplant Patients https://ClinicalTrials.gov/show/NCT03800758 Recruiting Northwestern University 2022-06-30
NCT03795779 CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03795779 Recruiting iCell Gene Therapeutics 2020-09-30
NCT03783403 A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Subjects With Advanced Solid and Hematologic Cancers https://ClinicalTrials.gov/show/NCT03783403 Recruiting Celgene 2022-12-30
NCT03765177 CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03765177 Recruiting Ottawa Hospital Research Institute 2022-10-31
NCT03757000 A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03757000 Recruiting Shanghai YingLi Pharmaceutical Co. Ltd. 2019-03-30
NCT03743480 Early Palliative Care and Hematological Cancer Patients https://ClinicalTrials.gov/show/NCT03743480 Recruiting Arcispedale Santa Maria Nuova-IRCCS 2020-11-30
NCT03735992 Mind-body Medicine for Patients With Malignant Hematological Diseases https://ClinicalTrials.gov/show/NCT03735992 Recruiting Universität Duisburg-Essen 2020-12-30
NCT03733340 Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT https://ClinicalTrials.gov/show/NCT03733340 Recruiting Nanfang Hospital of Southern Medical University 2019-12-01
NCT03717480 Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03717480 Recruiting Dana-Farber Cancer Institute 2022-05-01
NCT03712878 2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies https://ClinicalTrials.gov/show/NCT03712878 Recruiting Thomas Jefferson University 2020-12-31
NCT03699631 PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant https://ClinicalTrials.gov/show/NCT03699631 Active, not recruiting Medical College of Wisconsin 2021-02-01
NCT03680092 Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation in Patients With Hematologic Malignancy https://ClinicalTrials.gov/show/NCT03680092 Recruiting University of California, San Diego 2020-08-31
NCT03654404 Development of a Positive Psychology Intervention to Improve Mood and HRQoL in Patients Post-HSCT - Proof of Concept https://ClinicalTrials.gov/show/NCT03654404 Recruiting Dana-Farber Cancer Institute 2020-06-30
NCT03648372 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19) https://ClinicalTrials.gov/show/NCT03648372 Recruiting Takeda 2021-02-16
NCT03598608 Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) https://ClinicalTrials.gov/show/NCT03598608 Recruiting Merck Sharp & Dohme Corp. 2025-11-05
NCT03588936 Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant https://ClinicalTrials.gov/show/NCT03588936 Active, not recruiting Medical College of Wisconsin 2021-08-01
NCT03588598 Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03588598 Recruiting Nanjing Sanhome Pharmaceutical, Co., Ltd. 2019-07-31
NCT03580655 (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis https://ClinicalTrials.gov/show/NCT03580655 Recruiting Blueprint Medicines Corporation 2022-05-31
NCT03557619 A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies https://ClinicalTrials.gov/show/NCT03557619 Recruiting AbbVie 2021-06-04
NCT03555955 A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 https://ClinicalTrials.gov/show/NCT03555955 Recruiting Jazz Pharmaceuticals 2021-01-31
NCT03537482 APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03537482 Recruiting Ascentage Pharma Group Inc. 2020-09-15
NCT03531736 T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia https://ClinicalTrials.gov/show/NCT03531736 Recruiting Memorial Sloan Kettering Cancer Center 2021-05-31
NCT03512340 Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers https://ClinicalTrials.gov/show/NCT03512340 Active, not recruiting Surface Oncology 2020-09-18
NCT03483324 Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation https://ClinicalTrials.gov/show/NCT03483324 Recruiting Angiocrine Bioscience 2020-06-30
NCT03483194 Therapeutic Virtual Reality : Impact on the Management of Pain and Anxiety Related to Hematology Care (REVEH) https://ClinicalTrials.gov/show/NCT03483194 Completed Weprom 2020-04-20
NCT03471260 Ivosidenib and Venetoclax With or Without Azacitidine in Treating Participants With IDH1 Mutated Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03471260 Recruiting M.D. Anderson Cancer Center 2021-09-30
NCT03459170 Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant https://ClinicalTrials.gov/show/NCT03459170 Recruiting Bellicum Pharmaceuticals 2020-03-31
NCT03434704 Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole https://ClinicalTrials.gov/show/NCT03434704 Recruiting IRCCS San Raffaele 2020-03-15
NCT03431090 Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia https://ClinicalTrials.gov/show/NCT03431090 Recruiting Nationwide Children’s Hospital 2021-12-31
NCT03422679 Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies https://ClinicalTrials.gov/show/NCT03422679 Recruiting Cellestia Biotech AG 2021-06-30
NCT03413800 Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant https://ClinicalTrials.gov/show/NCT03413800 Recruiting Ciusss de L’Est de l’ÃŽle de Montréal 2021-01-29
NCT01260545 Study of CA-18C3 in Subjects With Advanced Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01260545 Completed XBiotech, Inc. 2012-06-30
NCT01254630 A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011) https://ClinicalTrials.gov/show/NCT01254630 Completed Merck Sharp & Dohme Corp. 2017-04-11
NCT01247701 Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies https://ClinicalTrials.gov/show/NCT01247701 Active, not recruiting Baylor College of Medicine 2024-11-30
NCT01246206 Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT https://ClinicalTrials.gov/show/NCT01246206 Completed Barbara Ann Karmanos Cancer Institute 2013-10-31
NCT01244906 Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant https://ClinicalTrials.gov/show/NCT01244906 Completed Northside Hospital, Inc. 2014-04-30
NCT01237639 Study of Red Blood Cell Transfusion Triggers in Patients Undergoing Hematopoietic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT01237639 Completed Ottawa Hospital Research Institute 2016-10-31
NCT01231412 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01231412 Completed Fred Hutchinson Cancer Research Center 2016-10-08
NCT01221857 Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01221857 Completed Gamida Cell ltd 2012-09-30
NCT01204164 Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies https://ClinicalTrials.gov/show/NCT01204164 Completed Tragara Pharmaceuticals, Inc. 2016-03-31
NCT01203722 Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01203722 Recruiting Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2023-09-30
NCT01195311 A Dose-escalation Study in Subjects With Advanced Malignancies https://ClinicalTrials.gov/show/NCT01195311 Completed Incyte Corporation 2013-05-31
NCT01188798 Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01188798 Completed St. Jude Children’s Research Hospital 2012-02-29
NCT01186809 Cytokine Induced Killer (CIK) Cells In Leukemia Patients https://ClinicalTrials.gov/show/NCT01186809 Completed A.O. Ospedale Papa Giovanni XXIII 2016-09-30
NCT01175785 Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01175785 Completed Nohla Therapeutics, Inc. 2014-08-31
NCT01162096 Reduced Intensity Haploidentical Transplant for Hematological Malignancies https://ClinicalTrials.gov/show/NCT01162096 Completed Thomas Jefferson University 2010-09-30
NCT01139151 4’-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01139151 Completed M.D. Anderson Cancer Center 2011-11-30
NCT01119066 HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01119066 Recruiting Memorial Sloan Kettering Cancer Center 2021-05-31
NCT01110473 ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01110473 Completed AbbVie 2013-06-30
NCT01093586 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01093586 Completed Case Comprehensive Cancer Center 2015-12-31
NCT01086735 Suicide Gene Therapy for Donor Lymphocytes Infusion After Allogeneic Hematopoietic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT01086735 Completed Assistance Publique - Hôpitaux de Paris 2012-11-30
NCT01084252 Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies https://ClinicalTrials.gov/show/NCT01084252 Active, not recruiting Sanofi 2018-12-21
NCT01081405 Total Lymphoid Irradiation and Anti-Thymocyte Globulin in the Allogeneic Hematopoietic Cell Transplantation https://ClinicalTrials.gov/show/NCT01081405 Recruiting Fondazione Neoplasie Sangue Onlus 2020-11-30
NCT01063647 Dose-range Finding Treosulfan-based Conditioning https://ClinicalTrials.gov/show/NCT01063647 Completed medac GmbH 2005-06-30
NCT01036009 A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01036009 Completed University of California, San Francisco 2014-07-31
NCT01034475 Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01034475 Completed Wake Forest University Health Sciences 2013-06-30
NCT01010217 Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide https://ClinicalTrials.gov/show/NCT01010217 Completed M.D. Anderson Cancer Center 2017-10-05
NCT00997386 Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States https://ClinicalTrials.gov/show/NCT00997386 Completed University of Arizona 2014-04-30
NCT00993486 Dose-ranging Study of a Single Administration of T-cell Add-back Depleted of Host Alloreactive Cells in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor https://ClinicalTrials.gov/show/NCT00993486 Completed Kiadis Pharma 2008-10-31
NCT00990717 Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies https://ClinicalTrials.gov/show/NCT00990717 Completed University Health Network, Toronto 2012-07-31
NCT00990587 Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy https://ClinicalTrials.gov/show/NCT00990587 Completed University Health Network, Toronto 2013-05-31
NCT00987987 Amplifying Graft-Versus-Tumor Effect by Donor Regulatory T-Cell Depletion Before Donor Lymphocytes Infusion https://ClinicalTrials.gov/show/NCT00987987 Completed Assistance Publique - Hôpitaux de Paris 2009-12-31
NCT00968630 Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer https://ClinicalTrials.gov/show/NCT00968630 Completed Fred Hutchinson Cancer Research Center 2017-03-17
NCT00953758 A Study Of PF-04449913 In Select Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00953758 Completed Pfizer 2012-09-30
NCT00943592 Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00943592 Completed University of Chicago 2011-04-30
NCT00943319 Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00943319 Completed University of Chicago 2017-12-31
NCT00914849 Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies https://ClinicalTrials.gov/show/NCT00914849 Completed Washington University School of Medicine 2011-01-31
NCT00908167 Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00908167 Completed St. Jude Children’s Research Hospital 2015-06-30
NCT00904787 Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies https://ClinicalTrials.gov/show/NCT00904787 Completed CASI Pharmaceuticals, Inc. 2010-12-31
NCT00900614 Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer https://ClinicalTrials.gov/show/NCT00900614 Completed Aprea Therapeutics 2010-10-31
NCT00897260 Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders https://ClinicalTrials.gov/show/NCT00897260 Completed University of British Columbia 2013-01-09
NCT00894049 A Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation https://ClinicalTrials.gov/show/NCT00894049 Completed Institut Paoli-Calmettes 2013-02-28
NCT00893555 Pharmacologic Optimization of Voriconazole https://ClinicalTrials.gov/show/NCT00893555 Completed University Medical Center Groningen 2016-11-30
NCT00892502 Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy? https://ClinicalTrials.gov/show/NCT00892502 Completed Copenhagen University Hospital at Herlev 2012-01-31
NCT00891137 Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy https://ClinicalTrials.gov/show/NCT00891137 Completed Cellerant Therapeutics 2014-06-30
NCT00890500 Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies. https://ClinicalTrials.gov/show/NCT00890500 Completed Fate Therapeutics 2013-05-31
NCT00881946 Repeat Dose Safety Study for Compound to Treat Hematologic Cancer https://ClinicalTrials.gov/show/NCT00881946 Completed Accenture 2012-03-31
NCT00867230 FTS Study in Patients With Advanced Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00867230 Completed M.D. Anderson Cancer Center 2009-02-28
NCT00845819 Study of Epidermal Growth Factor on Oral Mucositis Induced by Intensive Chemotherapy for Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00845819 Completed Seoul National University Hospital 2014-10-31
NCT00843947 Reduced Intensity Stem Cell Transplantation (RIST) for Patients With Hematological Malignancies Conditioned With Fludarabine and Busulfan https://ClinicalTrials.gov/show/NCT00843947 Completed University of California, Davis 2013-11-30
NCT00841724 Study of a Reduced-toxicity “Submyeloablative” Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT00841724 Completed Nantes University Hospital 2012-01-31
NCT00840190 A Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies https://ClinicalTrials.gov/show/NCT00840190 Completed Piramal Enterprises Limited 2011-03-31
NCT03711604 Compassionate Use Study of Tenalisib (RP6530) https://ClinicalTrials.gov/show/NCT03711604 Enrolling by invitation Rhizen Pharmaceuticals SA 2020-10-31
NCT02458235 Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT02458235 Active, not recruiting University of California, San Francisco 2020-03-31
NCT00825487 Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00825487 Completed ArQule 2011-05-31
NCT00824993 Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients https://ClinicalTrials.gov/show/NCT00824993 Completed M.D. Anderson Cancer Center 2017-04-07
NCT00824135 Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00824135 Completed St. Jude Children’s Research Hospital 2012-10-31
NCT02921685 Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT02921685 Recruiting Institut Paoli-Calmettes 2019-05-28
NCT00810602 Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00810602 Completed University of Michigan Rogel Cancer Center 2013-04-30
NCT00807677 A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00807677 Completed Millennium Pharmaceuticals, Inc. 2012-09-30
NCT01949545 Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment https://ClinicalTrials.gov/show/NCT01949545 Completed Amgen 2015-08-31
NCT01399840 Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies https://ClinicalTrials.gov/show/NCT01399840 Completed Pfizer 2014-03-31
NCT03878524 Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial https://ClinicalTrials.gov/show/NCT03878524 Recruiting OHSU Knight Cancer Institute 2022-02-27
NCT01822509 Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01822509 Active, not recruiting National Cancer Institute (NCI) 2018-12-31
NCT04303091 The Feasibility of a Physical Activity Intervention for Advanced Multiple Myeloma Patients https://ClinicalTrials.gov/show/NCT04303091 Completed University of Calgary 2018-12-20
NCT03262220 Total Marrow Irradiation With Volumetric Arc Therapy for Patients Unfit for a 12 Gy TBI https://ClinicalTrials.gov/show/NCT03262220 Recruiting University Hospital, Geneva 2021-04-30
NCT03082677 Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03082677 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-03-31
NCT02730299 Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard Umbilical Cord Blood in Patients With Leukemia, Lymphoma, and Myelodysplastic Syndrome (MDS) https://ClinicalTrials.gov/show/NCT02730299 Active, not recruiting Gamida Cell ltd 2019-12-31
NCT02566395 Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02566395 Recruiting Northwell Health 2021-12-31
NCT02528682 MiHA-loaded PD-L-silenced DC Vaccination After Allogeneic SCT https://ClinicalTrials.gov/show/NCT02528682 Recruiting Radboud University 2020-05-31
NCT03241550 A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients https://ClinicalTrials.gov/show/NCT03241550 Completed Astellas Pharma Inc 2019-07-05
NCT01300026 AMG 319 Lymphoid Malignancy FIH https://ClinicalTrials.gov/show/NCT01300026 Completed Amgen 2013-10-31
NCT01816230 Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM https://ClinicalTrials.gov/show/NCT01816230 Completed Gamida Cell ltd 2017-06-30
NCT03894150 A Study of F0002-ADC in Chinese Patients With Refractory or Recurrent CD30+ Hematologic Malignancies. https://ClinicalTrials.gov/show/NCT03894150 Recruiting Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 2021-03-01
NCT03838926 Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03838926 Recruiting Vanda Pharmaceuticals 2020-08-31
NCT00886522 Intrabone Infusion of Cord Blood in Adults With Hematological Malignancies https://ClinicalTrials.gov/show/NCT00886522 Completed St. Orsola Hospital 2012-05-31
NCT00788684 Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers https://ClinicalTrials.gov/show/NCT00788684 Active, not recruiting AbbVie 2022-05-02
NCT00780052 Infusional C-myb ASODN in Advanced Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00780052 Completed Abramson Cancer Center of the University of Pennsylvania 2011-08-31
NCT00763490 Trial Of Double Umbilical Cord Blood Transplantation https://ClinicalTrials.gov/show/NCT00763490 Completed University of Michigan Rogel Cancer Center 2013-03-31
NCT00750737 Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) https://ClinicalTrials.gov/show/NCT00750737 Completed M.D. Anderson Cancer Center 2012-06-30
NCT00749502 A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8) https://ClinicalTrials.gov/show/NCT00749502 Completed Tesaro, Inc. 2011-09-30
NCT00742560 A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma https://ClinicalTrials.gov/show/NCT00742560 Completed AbbVie 2016-10-31
NCT00741455 Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00741455 Active, not recruiting Dartmouth-Hitchcock Medical Center 2023-01-31
NCT00741234 A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine https://ClinicalTrials.gov/show/NCT00741234 Completed S*BIO 2012-03-31
NCT00739141 Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. https://ClinicalTrials.gov/show/NCT00739141 Active, not recruiting Memorial Sloan Kettering Cancer Center 2020-08-31
NCT00722488 Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma https://ClinicalTrials.gov/show/NCT00722488 Completed Millennium Pharmaceuticals, Inc. 2013-07-31
NCT00718757 Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00718757 Completed St. Jude Children’s Research Hospital 2009-01-31
NCT00710528 Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00710528 Completed Gilead Sciences 2011-12-31
NCT00697671 Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00697671 Completed St. Jude Children’s Research Hospital 2013-02-28
NCT00697346 Study of MLN8237 in Participants With Advanced Hematological Malignancies https://ClinicalTrials.gov/show/NCT00697346 Completed Takeda 2016-10-01
NCT00693927 Nonmyeloablative Stem Cell Transplantation With CD8-depleted or Unmanipulated Peripheral Blood Stem Cells (PBSC) https://ClinicalTrials.gov/show/NCT00693927 Completed University of Liege 2005-05-31
NCT00683046 T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00683046 Completed University of Chicago 2014-12-31
NCT00677859 Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia https://ClinicalTrials.gov/show/NCT00677859 Completed Athersys, Inc 2011-10-31
NCT00674479 INCB018424 in Patients With Advanced Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00674479 Completed M.D. Anderson Cancer Center 2017-03-23
NCT00673114 Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies https://ClinicalTrials.gov/show/NCT00673114 Completed Duke University 2012-04-30
NCT00660920 Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies https://ClinicalTrials.gov/show/NCT00660920 Completed Takeda 2016-05-31
NCT00642031 Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00642031 Completed Prescient Therapeutics, Ltd. 2012-10-31
NCT00640796 Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors https://ClinicalTrials.gov/show/NCT00640796 Completed St. Jude Children’s Research Hospital 2014-04-30
NCT00623870 A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms. https://ClinicalTrials.gov/show/NCT00623870 Completed Hoffmann-La Roche 2012-11-30
NCT00621244 A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies https://ClinicalTrials.gov/show/NCT00621244 Completed Novartis 2009-12-03
NCT00618969 Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors https://ClinicalTrials.gov/show/NCT00618969 Completed University of Arizona 2013-12-31
NCT00597519 A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy https://ClinicalTrials.gov/show/NCT00597519 Completed Memorial Sloan Kettering Cancer Center 2015-09-30
NCT00595686 Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies https://ClinicalTrials.gov/show/NCT00595686 Completed Esanex Inc. 2010-05-31
NCT00592046 A Phase I Trial of ZIO-101 in Hematologic Cancers https://ClinicalTrials.gov/show/NCT00592046 Completed Ziopharm 2008-06-30
NCT00582894 Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases https://ClinicalTrials.gov/show/NCT00582894 Completed University of Oklahoma 2008-03-31
NCT00558675 A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy https://ClinicalTrials.gov/show/NCT00558675 Completed Immunovative Therapies, Ltd. 2012-12-31
NCT00557817 Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT) https://ClinicalTrials.gov/show/NCT00557817 Completed University of Liege 2008-08-31
NCT00556452 Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen https://ClinicalTrials.gov/show/NCT00556452 Completed University of Michigan Rogel Cancer Center 2011-06-30
NCT00533078 Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT00533078 Completed University Hospital Inselspital, Berne 2009-12-31
NCT00526045 Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients https://ClinicalTrials.gov/show/NCT00526045 Completed Novartis 2012-04-30
NCT00521859 Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00521859 Completed M.D. Anderson Cancer Center 2010-12-31
NCT00514579 Adult Double Cord Blood Transplant Study https://ClinicalTrials.gov/show/NCT00514579 Completed Center for International Blood and Marrow Transplant Research 2013-08-31
NCT00506857 Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support https://ClinicalTrials.gov/show/NCT00506857 Completed M.D. Anderson Cancer Center 2011-08-31
NCT00506402 A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00506402 Completed CASI Pharmaceuticals, Inc. 2009-01-31
NCT00504803 Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease https://ClinicalTrials.gov/show/NCT00504803 Completed University of Liege 2010-12-31
NCT00500578 Intermittent Use of Aerosolized Ribavirin for Treatment of RSV https://ClinicalTrials.gov/show/NCT00500578 Completed M.D. Anderson Cancer Center 2009-01-31
NCT00496340 Phase II Trial of Pentostatin and Targeted Busulfan https://ClinicalTrials.gov/show/NCT00496340 Completed H. Lee Moffitt Cancer Center and Research Institute 2013-04-30
NCT00477542 A Phase I Trial of Myeloablative Conditioning w/ Clofarabine and HD Busulfan for Pts w/ Refractory Heme Malignancies Undergoing Allo PBSCT https://ClinicalTrials.gov/show/NCT00477542 Completed Indiana University 2010-11-30
NCT00477035 Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00477035 Completed Stanford University 2011-03-31
NCT00476177 Donor Dendritic Cells And Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogeneic Transplant https://ClinicalTrials.gov/show/NCT00476177 Completed Dana-Farber Cancer Institute 2007-08-31
NCT00473577 Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients https://ClinicalTrials.gov/show/NCT00473577 Completed Pharmacyclics LLC. 2007-11-30
NCT00472368 A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589 https://ClinicalTrials.gov/show/NCT00472368 Completed Novartis 2008-06-30
NCT00469729 Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy https://ClinicalTrials.gov/show/NCT00469729 Completed Gamida Cell -Teva Joint Venture Ltd. 2013-02-28
NCT00460694 Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies https://ClinicalTrials.gov/show/NCT00460694 Completed Singapore General Hospital 2012-12-31
NCT00438178 Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies https://ClinicalTrials.gov/show/NCT00438178 Completed Teva Pharmaceutical Industries 2007-10-31
NCT00430846 Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00430846 Completed Seattle Genetics, Inc. 2009-07-31
NCT00429416 Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00429416 Completed Thomas Jefferson University 2008-12-31
NCT00429143 A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative https://ClinicalTrials.gov/show/NCT00429143 Completed Thomas Jefferson University 2009-08-31
NCT00423124 Infusion of Donor Lymphocytes Transduced With the Suicide Gene HSV TK in Patients With Haematological Malignancies https://ClinicalTrials.gov/show/NCT00423124 Completed MolMed S.p.A. 2011-12-31
NCT00421213 Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers https://ClinicalTrials.gov/show/NCT00421213 Completed Ziopharm 2012-04-30
NCT00820560 Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors https://ClinicalTrials.gov/show/NCT00820560 Completed Incyte Corporation 2009-01-31
NCT00410696 Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy https://ClinicalTrials.gov/show/NCT00410696 Completed Istituto Clinico Humanitas 2008-11-30
NCT00405743 A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00405743 Completed Clavis Pharma 2009-05-31
NCT00402714 A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies https://ClinicalTrials.gov/show/NCT00402714 Completed Yale University 2009-07-31
NCT00389428 Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer. https://ClinicalTrials.gov/show/NCT00389428 Completed Jazz Pharmaceuticals 2008-12-31
NCT00382759 Nonmyeloablative Stem Cell Transplant in Elderly https://ClinicalTrials.gov/show/NCT00382759 Completed Azienda Ospedaliera San Giovanni Battista 2007-03-31
NCT00379587 Rituximab for Prevention of Chronic GVHD https://ClinicalTrials.gov/show/NCT00379587 Completed Dana-Farber Cancer Institute 2012-08-31
NCT00369226 Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00369226 Completed Dana-Farber Cancer Institute 2010-07-31
NCT00367588 Low Bacterial Diet in Patients With Cytopenia https://ClinicalTrials.gov/show/NCT00367588 Completed Maastricht University Medical Center NA
NCT00355407 Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00355407 Completed Dana-Farber Cancer Institute 2007-08-31
NCT00348959 An Evaluation of the Effect of ‘Open Window’ on Psychological Well-being and Experience of Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00348959 Completed St. James’s Hospital, Ireland 2010-01-31
NCT00343798 A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00343798 Completed Fred Hutchinson Cancer Research Center 2013-07-31
NCT00333190 CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00333190 Completed Dana-Farber Cancer Institute 2007-03-31
NCT00312429 Umbilical Cord Blood Stem Cell Transplantation in Adults With Advanced Blood Disorders or Cancer https://ClinicalTrials.gov/show/NCT00312429 Completed Duke University 2008-05-31
NCT00273936 Trial of AVN-944 in Patients With Advanced Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00273936 Completed Vertex Pharmaceuticals Incorporated NA
NCT00270881 Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00270881 Completed Keio University 2009-01-31
NCT00246662 Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00246662 Completed Sunesis Pharmaceuticals 2008-12-23
NCT00241358 Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT00241358 Completed Washington University School of Medicine 2009-12-31
NCT00231309 Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT) https://ClinicalTrials.gov/show/NCT00231309 Completed Emory University 2011-11-30
NCT00208962 Allogeneic Cell Therapy for Adults With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00208962 Completed Emory University 2007-09-30
NCT00208923 Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00208923 Completed Emory University 2007-10-31
NCT00202917 Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00202917 Completed University Hospital Tuebingen 2009-07-31
NCT00189488 Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation https://ClinicalTrials.gov/show/NCT00189488 Completed Swedish Orphan Biovitrum 2008-11-30
NCT00186823 Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00186823 Completed St. Jude Children’s Research Hospital 2005-09-30
NCT00186342 Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00186342 Completed Stanford University 2009-01-31
NCT00186225 Stem Cell Transplant From Matched Unrelated or Partially Matched Related Donors https://ClinicalTrials.gov/show/NCT00186225 Completed Stanford University 2007-06-30
NCT00185640 Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00185640 Completed Stanford University 2014-04-30
NCT00179764 Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC]) https://ClinicalTrials.gov/show/NCT00179764 Completed Ann & Robert H Lurie Children’s Hospital of Chicago 2014-01-24
NCT00165282 Mindfulness Meditation in Bone Marrow Transplantation https://ClinicalTrials.gov/show/NCT00165282 Completed Emory University 2010-01-31
NCT00152139 Stem Cell Transplantation for Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00152139 Completed St. Jude Children’s Research Hospital 2005-06-30
NCT00150462 Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT00150462 Completed Amgen 2009-10-31
NCT00146614 Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00146614 Completed Dana-Farber Cancer Institute 2003-04-30
NCT00145626 HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00145626 Completed St. Jude Children’s Research Hospital 2015-03-31
NCT00145613 Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies https://ClinicalTrials.gov/show/NCT00145613 Completed St. Jude Children’s Research Hospital 2006-07-31
NCT00144703 Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00144703 Completed Dana-Farber Cancer Institute 2006-11-30
NCT00143559 Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00143559 Completed St. Jude Children’s Research Hospital 2006-07-31
NCT00138112 Trial of Prophylactic Versus Empirical Vancomycin for the Prevention of Streptococcal Sepsis After Hematopoietic Cell Transplantation https://ClinicalTrials.gov/show/NCT00138112 Completed Memorial Sloan Kettering Cancer Center NA
NCT00003395 Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer https://ClinicalTrials.gov/show/NCT00003395 Completed Memorial Sloan Kettering Cancer Center 2000-03-31
NCT00088101 STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors https://ClinicalTrials.gov/show/NCT00088101 Completed Synta Pharmaceuticals Corp. NA
NCT00086125 Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED) https://ClinicalTrials.gov/show/NCT00086125 Completed Merck Sharp & Dohme Corp. 2006-06-30
NCT00080925 T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00080925 Completed National Institutes of Health Clinical Center (CC) NA
NCT00005799 Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer https://ClinicalTrials.gov/show/NCT00005799 Completed Fred Hutchinson Cancer Research Center 2002-07-31
NCT00079391 Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies https://ClinicalTrials.gov/show/NCT00079391 Completed National Institutes of Health Clinical Center (CC) 2008-12-31
NCT00078858 Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00078858 Completed Fred Hutchinson Cancer Research Center 2006-01-31
NCT00077181 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00077181 Completed National Cancer Institute (NCI) 2008-07-31
NCT00070538 VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00070538 Completed National Cancer Institute (NCI) 2004-09-30
NCT00068523 Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00068523 Completed Case Comprehensive Cancer Center 2004-03-31
NCT00067730 A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation https://ClinicalTrials.gov/show/NCT00067730 Completed Eli Lilly and Company NA
NCT00061620 Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00061620 Completed M.D. Anderson Cancer Center 2004-02-12
NCT00056966 Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases https://ClinicalTrials.gov/show/NCT00056966 Completed Baylor College of Medicine 2005-05-31
NCT00027820 Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer https://ClinicalTrials.gov/show/NCT00027820 Completed Fred Hutchinson Cancer Research Center 2004-09-30
NCT00006379 Non-Ablative Allo HSCT For Hematologic Malignancies or SAA https://ClinicalTrials.gov/show/NCT00006379 Completed Case Comprehensive Cancer Center 2004-01-31
NCT00051597 A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00051597 Completed Seattle Genetics, Inc. NA
NCT00051311 Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers https://ClinicalTrials.gov/show/NCT00051311 Completed National Institutes of Health Clinical Center (CC) 2014-09-25
NCT00001748 HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies https://ClinicalTrials.gov/show/NCT00001748 Completed National Institutes of Health Clinical Center (CC) NA
NCT00047489 Study of ABT-751 in Patients With Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00047489 Completed M.D. Anderson Cancer Center 2005-01-31
NCT00044759 Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma https://ClinicalTrials.gov/show/NCT00044759 Completed Wyeth is now a wholly owned subsidiary of Pfizer NA
NCT00795132 Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00795132 Completed University of Utah 2009-07-31
NCT00042250 IUdR/BUdR Cell Cycle Labelling https://ClinicalTrials.gov/show/NCT00042250 Completed M.D. Anderson Cancer Center 2002-10-31
NCT00041665 Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy https://ClinicalTrials.gov/show/NCT00041665 Completed Amgen NA
NCT00038376 Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies https://ClinicalTrials.gov/show/NCT00038376 Completed M.D. Anderson Cancer Center 2005-06-30
NCT00028418 Clofarabine in Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT00028418 Completed FDA Office of Orphan Products Development NA
NCT00603954 Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings https://ClinicalTrials.gov/show/NCT00603954 Completed University of Liege 2011-03-31
NCT00675831 Infusion of Donor Lymphocytes Depleted of CD25+ Regulatory T-cells in Patients With Relapsed Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00675831 Completed Dana-Farber Cancer Institute 2013-01-31
NCT00013533 Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies https://ClinicalTrials.gov/show/NCT00013533 Completed National Institutes of Health Clinical Center (CC) 2008-03-01
NCT00005785 Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer https://ClinicalTrials.gov/show/NCT00005785 Completed National Institutes of Health Clinical Center (CC) NA
NCT00001873 The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers https://ClinicalTrials.gov/show/NCT00001873 Completed National Institutes of Health Clinical Center (CC) 2007-12-28
NCT00001623 Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia https://ClinicalTrials.gov/show/NCT00001623 Completed National Institutes of Health Clinical Center (CC) 2008-01-31

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03377010 UF-BMT-HSCT-001: A Non-Interventional Study Evaluating Diet in HSCT Survivors https://ClinicalTrials.gov/show/NCT03377010 Completed University of Florida 2019-09-13
NCT02990130 Patient Fitness and Body Composition During Hematopoietic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT02990130 Recruiting Garcia, Jose M., MD, PhD 2019-12-31
NCT03316209 Identification of Occupational Exposures in Acute Hematologic Malignancy https://ClinicalTrials.gov/show/NCT03316209 Recruiting Centre Hospitalier Intercommunal Creteil 2020-03-31
NCT03222258 Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients https://ClinicalTrials.gov/show/NCT03222258 Active, not recruiting Seoul National University Hospital 2019-10-31
NCT02949427 The Oronasal Microbiota in Pediatric Oncology Patients https://ClinicalTrials.gov/show/NCT02949427 Recruiting St. Jude Children’s Research Hospital 2021-11-30
NCT02906254 Early Antibiotic Discontinuation in FUO https://ClinicalTrials.gov/show/NCT02906254 Completed University Hospital, Brest 2015-09-30
NCT02885623 Role of CX3CR1-expressing Cells in Hematologic Malignancy https://ClinicalTrials.gov/show/NCT02885623 Recruiting Saint Vincent’s Hospital, Korea 2019-08-31
NCT02884375 Elderly CAncer Patient https://ClinicalTrials.gov/show/NCT02884375 Recruiting Assistance Publique - Hôpitaux de Paris 2027-11-30
NCT02859623 Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN) https://ClinicalTrials.gov/show/NCT02859623 Completed Centre Hospitalier Universitaire de Besancon 2015-05-31
NCT02844400 Cancer Patients’ Performance Status Assessed Using Cardiopulmonary Exercise Testing and Wearable Data Generation https://ClinicalTrials.gov/show/NCT02844400 Completed UNC Lineberger Comprehensive Cancer Center 2018-12-31
NCT02842229 A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms https://ClinicalTrials.gov/show/NCT02842229 Completed Celgene 2017-02-02
NCT02828462 Impact of a Monitoring Device for Patients With Cancer Treated Using Oral Therapeutics https://ClinicalTrials.gov/show/NCT02828462 Recruiting Gustave Roussy, Cancer Campus, Grand Paris 2019-10-31
NCT02824159 Association Between Side Effects Occurrence and Concentrations of Ibrutinib and Idelalisib https://ClinicalTrials.gov/show/NCT02824159 Recruiting University Hospital, Toulouse 2020-11-30
NCT02786628 Assessing Physical Fitness in Cancer Patients With Cardiopulmonary Exercise Testing and Wearable Data Generation https://ClinicalTrials.gov/show/NCT02786628 Completed UNC Lineberger Comprehensive Cancer Center 2018-02-28
NCT02669706 Intravenous Pentamidine for Pneumocystis Jirovecii Pneumonia https://ClinicalTrials.gov/show/NCT02669706 Completed University of Illinois at Chicago 2016-05-31
NCT02636855 Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination https://ClinicalTrials.gov/show/NCT02636855 Recruiting Adaptimmune 2025-11-30
NCT02598752 Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation https://ClinicalTrials.gov/show/NCT02598752 Completed Memorial Sloan Kettering Cancer Center 2020-04-10
NCT01351545 A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) https://ClinicalTrials.gov/show/NCT01351545 Recruiting Center for International Blood and Marrow Transplant Research 2021-10-31
NCT00559065 A Case-Cohort Study of Hematopoietic Malignancies and Related Disorders and Lung Cancer in Benzene-Exposed Workers in China https://ClinicalTrials.gov/show/NCT00559065 Completed National Institutes of Health Clinical Center (CC) NA
NCT02562105 Prognosis of Hematological Cancer Patient Underwent Mechanical Ventillation https://ClinicalTrials.gov/show/NCT02562105 Completed Mansoura University 2015-08-31
NCT03391791 Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors https://ClinicalTrials.gov/show/NCT03391791 Enrolling by invitation Adaptimmune 2047-12-31
NCT02544230 Granulocyte Transfusions in Hematological Patients With Febrile Neutropenia https://ClinicalTrials.gov/show/NCT02544230 Completed Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne 2011-12-31
NCT02473757 Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies https://ClinicalTrials.gov/show/NCT02473757 Enrolling by invitation National Institutes of Health Clinical Center (CC) 2034-07-01
NCT02451592 Fungemia in Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02451592 Completed Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne 2015-12-31
NCT02338479 Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02338479 Active, not recruiting Center for International Blood and Marrow Transplant Research 2020-02-29
NCT02315599 Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials https://ClinicalTrials.gov/show/NCT02315599 Recruiting National Institutes of Health Clinical Center (CC) 2035-04-01
NCT02305979 Evaluation of Loratadine for G-CSF Induced Bone Pain in Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02305979 Completed Wake Forest University Health Sciences 2017-09-30
NCT02301065 Analysis of T Cell and Natural Killer (NK) Cell in Relation to Viral Infections in Pediatric Stem Cell Transplant Patients and Donors https://ClinicalTrials.gov/show/NCT02301065 Completed St. Jude Children’s Research Hospital 2017-02-06
NCT02269592 Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome https://ClinicalTrials.gov/show/NCT02269592 Recruiting Dana-Farber Cancer Institute 2024-12-31
NCT02199548 The Good Patient Study https://ClinicalTrials.gov/show/NCT02199548 Completed St. Jude Children’s Research Hospital 2015-05-31
NCT02164071 Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies https://ClinicalTrials.gov/show/NCT02164071 Completed Celgene 2013-12-03
NCT02134574 Prospective Cohort With Hemopathy in Languedoc-Roussillon https://ClinicalTrials.gov/show/NCT02134574 Recruiting University Hospital, Montpellier 2033-06-30
NCT01316549 Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation https://ClinicalTrials.gov/show/NCT01316549 Active, not recruiting University of California, San Francisco 2021-07-31
NCT01275534 Symptom Experience and Self-management After Haematopoietic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT01275534 Completed University Hospital, Basel, Switzerland 2012-11-30
NCT02041416 Technology to Assess Vulnerable Older Adults With Cancer and Their Caregivers https://ClinicalTrials.gov/show/NCT02041416 Active, not recruiting City of Hope Medical Center 2020-09-30
NCT02033928 Comprehensive Frailty Assessment https://ClinicalTrials.gov/show/NCT02033928 Completed Ohio State University Comprehensive Cancer Center 2017-08-31
NCT01997918 Secondary Haplo HSCT for Relapse After Initial Allogeneic HSCT https://ClinicalTrials.gov/show/NCT01997918 Completed University Hospital Tuebingen 2017-12-30
NCT01930981 Associations Between Pre-transplant Comorbidities and Post-transplant Toxicities and Quality of Life https://ClinicalTrials.gov/show/NCT01930981 Completed Fred Hutchinson Cancer Research Center 2016-06-30
NCT01869218 Feasibility Study of Genomic Sequencing to Find Potential Targets for Personalized Therapy https://ClinicalTrials.gov/show/NCT01869218 Active, not recruiting University of Colorado, Denver 2015-08-03
NCT01855698 PENELOPE Observational Study: Prophylaxis and Treatment of Arterial and Venous Thromboembolism https://ClinicalTrials.gov/show/NCT01855698 Completed Gruppo Italiano Malattie EMatologiche dell’Adulto 2018-03-15
NCT01821456 Cologne Cohort of Neutropenic Patients (CoCoNut) https://ClinicalTrials.gov/show/NCT01821456 Recruiting University Hospital of Cologne 2050-12-31
NCT01792882 Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples https://ClinicalTrials.gov/show/NCT01792882 Enrolling by invitation Global BioClinical 2020-12-31
NCT01775072 Genomic Profiling in Cancer Patients https://ClinicalTrials.gov/show/NCT01775072 Recruiting Memorial Sloan Kettering Cancer Center 2021-01-31
NCT01772771 Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program https://ClinicalTrials.gov/show/NCT01772771 Recruiting M.D. Anderson Cancer Center 2032-03-31
NCT01726699 Scripps Tumorgraft Study https://ClinicalTrials.gov/show/NCT01726699 Completed Scripps Translational Science Institute 2014-07-31
NCT01714180 Effect of Body Mass on Acyclovir Pharmacokinetics https://ClinicalTrials.gov/show/NCT01714180 Completed West Virginia University 2014-03-31
NCT03349372 Impact of Pulmonary Follow-up After Stem Cell Graft https://ClinicalTrials.gov/show/NCT03349372 Completed Hospices Civils de Lyon 2017-10-31
NCT01430663 Diagnosing Pulmonary Aspergillosis in Patients With Hematological Malignancies: A Multicentre Prospective Evaluation of an Aspergillus PCR Assay and a Galactomannan ELISA in Bronchoalveolar Lavage Samples https://ClinicalTrials.gov/show/NCT01430663 Completed Heidelberg University 2011-02-28
NCT01362179 National Marrow Donor Program Long-Term Donor Follow-Up https://ClinicalTrials.gov/show/NCT01362179 Active, not recruiting Center for International Blood and Marrow Transplant Research 2020-09-30
NCT04352556 COVID19-hematological Malignancies: the Italian Hematology Alliance https://ClinicalTrials.gov/show/NCT04352556 Recruiting Ospedale di Circolo - Fondazione Macchi 2021-04-30
NCT04290000 Collection of Biological Samples From Patients Treated With CAR-T Cells for Hematological Malignancies https://ClinicalTrials.gov/show/NCT04290000 Recruiting University Hospital, Montpellier 2025-02-25
NCT04287309 CAR-T Cellular Therapy for B Cell Malignancies Involved in CNS https://ClinicalTrials.gov/show/NCT04287309 Recruiting Zhejiang University 2022-02-28
NCT04264767 Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA https://ClinicalTrials.gov/show/NCT04264767 Recruiting Nucleix Ltd. 2026-12-31
NCT04235153 CAncer, NUtrition and Taste - Validation of the CANUT-QVA Questionnaire on Eating Habits in Cancer Patients https://ClinicalTrials.gov/show/NCT04235153 Recruiting Hospices Civils de Lyon 2020-03-31
NCT04142372 Tissue Microarray of Hematological Malignancies https://ClinicalTrials.gov/show/NCT04142372 Active, not recruiting Tampere University Hospital 2022-12-31
NCT03992352 Composite Health Assessment Risk Model (CHARM) for Older Adults https://ClinicalTrials.gov/show/NCT03992352 Recruiting Center for International Blood and Marrow Transplant Research 2022-07-31
NCT03978312 Nutrition Health Literacy of Cancer Patients and Their Support Networks. https://ClinicalTrials.gov/show/NCT03978312 Recruiting Nottingham University Hospitals NHS Trust 2019-09-01
NCT03960593 Cohort of Patients Over 70 Years of Age With Cancer and / or Hematological Malignancy https://ClinicalTrials.gov/show/NCT03960593 Recruiting Assistance Publique Hopitaux De Marseille 2019-01-01
NCT03955276 An Open Label Navigational Investigation of Molecular Profile-Related Evidence Determining Individualized Cancer Therapy for Patients With Incurable Hematologic Malignancies (I-PREDICT Heme) https://ClinicalTrials.gov/show/NCT03955276 Active, not recruiting University of California, San Diego 2022-08-07
NCT03896880 Detection of Bloodstream Pathogens in Hematological Malignancies https://ClinicalTrials.gov/show/NCT03896880 Recruiting Assiut University 2020-10-01
NCT03806712 Comprehensive Study of Social Representation of Platelet Transfusion in Patients Followed for Advanced Hematological Malignancies (R-PLQ) https://ClinicalTrials.gov/show/NCT03806712 Completed Centre Hospitalier Universitaire de Besancon 2019-06-01
NCT03802773 Cord Blood Transplantation With Myeloablative Conditioning and Post-transplant Cyclophosphamide (COmPACt Study) https://ClinicalTrials.gov/show/NCT03802773 Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS 2020-12-31
NCT03771079 MS Detection of Somatic Mutations in Hematological Malignancies https://ClinicalTrials.gov/show/NCT03771079 Recruiting University Hospital, Strasbourg, France 2019-12-31
NCT03750994 Economic Evaluation of Innovative Molecular Analyses in Onco-haematology https://ClinicalTrials.gov/show/NCT03750994 Recruiting Assistance Publique - Hôpitaux de Paris 2020-10-31
NCT03673631 Oxygenation Methods and Non-invasive Ventilation in Patients With Acute Respiratory Failure and a do Not Intubate Order https://ClinicalTrials.gov/show/NCT03673631 Recruiting Poitiers University Hospital 2020-01-31
NCT03609840 Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients https://ClinicalTrials.gov/show/NCT03609840 Recruiting University of California, San Francisco 2020-07-31
NCT03609827 Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients https://ClinicalTrials.gov/show/NCT03609827 Active, not recruiting University of California, San Francisco 2021-09-30
NCT03609814 Study of Clofarabine and Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation (HCT) https://ClinicalTrials.gov/show/NCT03609814 Active, not recruiting University of California, San Francisco 2020-07-31
NCT03505086 Bleeding In Thrombocytopenia Explained https://ClinicalTrials.gov/show/NCT03505086 Recruiting Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research 2022-10-01
NCT03469921 Unicentric Retrospective Analysis of a Cohort of 602 Young Adult and Adolescent Patients (AJA), Aged 15 to 30 Years, With Haematological Malignancies, and Managed Between 2000 and 2016 https://ClinicalTrials.gov/show/NCT03469921 Completed Institut Paoli-Calmettes 2016-12-31
NCT03449953 Critical Care Outcomes of Hematologic Oncology Patients https://ClinicalTrials.gov/show/NCT03449953 Recruiting Mount Sinai Hospital, Canada 2020-12-31
NCT03434561 Comparing Different Methods for Collection of Comorbidity Data Per the HCT-CI https://ClinicalTrials.gov/show/NCT03434561 Completed Fred Hutchinson Cancer Research Center 2016-06-30
NCT03419078 Nutrition and Outcomes of Hematopoietic Cell Transplantation (HCT) https://ClinicalTrials.gov/show/NCT03419078 Completed Imperial College Healthcare NHS Trust 2016-06-30
NCT01172132 The Use of Intensive Care in Critically Ill Cancer Haematological Patients: “TRIAL-OH” https://ClinicalTrials.gov/show/NCT01172132 Completed Assistance Publique - Hôpitaux de Paris 2011-05-31
NCT01166009 Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries https://ClinicalTrials.gov/show/NCT01166009 Recruiting Center for International Blood and Marrow Transplant Research 2025-07-31
NCT01069887 A Prospective Registry for Febrile Events in Patients With Malignant Hemopathies or Subjected to Haematopoietic Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01069887 Completed Catholic University of the Sacred Heart NA
NCT01060462 Observational Study Investigating the Response Rate of Itraconazole Injection in Treating Immunocompromised Patients https://ClinicalTrials.gov/show/NCT01060462 Completed Janssen Korea, Ltd., Korea 2009-02-28
NCT01021683 The Relationship of Defeverscence and Itraconazole Plasma Level Study in Immunocompromised Participants https://ClinicalTrials.gov/show/NCT01021683 Completed Janssen Korea, Ltd., Korea 2010-07-31
NCT00876148 Risk of Hepatitis B Virus Reactivation in Patients Undergoing Allografting https://ClinicalTrials.gov/show/NCT00876148 Completed Azienda Ospedaliera San Giovanni Battista NA
NCT02194868 Immunoregulatory T Lymphocytes Subtypes and Haematopoietic Stem Cell Transplantation (HSCT) https://ClinicalTrials.gov/show/NCT02194868 Active, not recruiting Assistance Publique - Hôpitaux de Paris 2020-04-30
NCT03212560 Exercise Capacity and Physical Activity Levels in Newly Diagnosed Hematologic Malignant Patients https://ClinicalTrials.gov/show/NCT03212560 Completed Gazi University 2018-09-30
NCT04093622 Long-term Follow-Up Study Following Treatment With Fate Therapeutics’ Engineered Cellular Immunotherapy https://ClinicalTrials.gov/show/NCT04093622 Recruiting Fate Therapeutics 2036-07-31
NCT00770523 Conditioning Regimen Before Infusion of Allogeneic Hematopoietic Stem Cells https://ClinicalTrials.gov/show/NCT00770523 Completed Cooperative Study Group A for Hematology 2008-03-31
NCT00719147 AVN of Weight-Bearing Joints In Patients With Hematologic Malignancies Treated With Dexamethasone Or Prednisone https://ClinicalTrials.gov/show/NCT00719147 Completed St. Jude Children’s Research Hospital 2005-07-31
NCT00695279 Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products https://ClinicalTrials.gov/show/NCT00695279 Recruiting St. Jude Children’s Research Hospital 2036-12-31
NCT00513175 Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia https://ClinicalTrials.gov/show/NCT00513175 Completed University of California, San Francisco NA
NCT00440765 VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands https://ClinicalTrials.gov/show/NCT00440765 Completed Janssen-Cilag B.V. 2012-01-31
NCT00440479 ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies. https://ClinicalTrials.gov/show/NCT00440479 Completed Janssen-Cilag B.V. 2011-01-31
NCT00195533 Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients https://ClinicalTrials.gov/show/NCT00195533 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2005-03-31
NCT00071045 Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members https://ClinicalTrials.gov/show/NCT00071045 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT00159003 Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in Israel https://ClinicalTrials.gov/show/NCT00159003 Completed Hadassah Medical Organization 2017-07-01
NCT00001872 Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease https://ClinicalTrials.gov/show/NCT00001872 Completed National Institutes of Health Clinical Center (CC) NA
NCT00001432 The Collection of Peripheral Blood Lymphocytes and Marrow Progenitor Cells From Normal Volunteers and Volunteers With Lymphoid or Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00001432 Completed National Institutes of Health Clinical Center (CC) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03301493 Genomic Testing and Resulting Medical Decisions https://ClinicalTrials.gov/show/NCT03301493 Recruiting Arbeitsgemeinschaft medikamentoese Tumortherapie 2019-12-31
NCT03288441 Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia https://ClinicalTrials.gov/show/NCT03288441 Recruiting Maastricht University Medical Center 2019-07-31
NCT03221075 Clinical Implications of Azole-Resistant Aspergillosis in Hematological Malignancy https://ClinicalTrials.gov/show/NCT03221075 Recruiting University Hospital of Cologne 2020-06-01
NCT03023202 UWCCC Molecular Tumor Board Registry https://ClinicalTrials.gov/show/NCT03023202 Recruiting University of Wisconsin, Madison 2021-03-31
NCT02835911 Clinical Cohort of Lymphoma Patients in Malawi https://ClinicalTrials.gov/show/NCT02835911 Recruiting UNC Lineberger Comprehensive Cancer Center 2020-12-31
NCT02457962 Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study https://ClinicalTrials.gov/show/NCT02457962 Recruiting Mayo Clinic 2020-04-30
NCT02298816 B-Cell Hematologic Malignancy Vaccination Registry https://ClinicalTrials.gov/show/NCT02298816 Enrolling by invitation Aurora Health Care 2024-12-31
NCT04389541 Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology https://ClinicalTrials.gov/show/NCT04389541 Recruiting iOMEDICO AG 2023-06-30
NCT04263857 Register of Blood Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT04263857 Recruiting Technische Universität München 2037-11-30
NCT04236063 Rehabilitation Needs of the Malaysian Haematological Cancer Survivors https://ClinicalTrials.gov/show/NCT04236063 Recruiting University of Malaya 2020-05-31
NCT04024995 Revision of Antifungal Strategies Definitions for Invasive Fungal Infections in Hematological Malignancies https://ClinicalTrials.gov/show/NCT04024995 Recruiting Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne 2020-03-31
NCT03575767 Characteristics and Dynamics of TCR Repertoire in Patients With Hematological Malignancies After Allo-HSCT https://ClinicalTrials.gov/show/NCT03575767 Completed Affiliated Hospital to Academy of Military Medical Sciences 2018-08-20